Wayel Jassem, Emmanuel Xystrakis, Yasmeen G. Ghnewa, Muhammed Yuksel, Oltin Pop, Marc Martinez‐Llordella, Yamen Jabri, Xiaohong Huang, Juan J. Lozano, Alberto Quaglia, Alberto Sanchez‐Fueyo, Constantin C. Coussios, Mohamed Rela, Peter Friend, Nigel Heaton, Yun Ma – 18 December 2018 – Liver transplantation (LT) is a successful treatment for patients with liver failure. However, organ shortage results in over 11% of patients losing their chance of a transplant attributed to liver decompensation (LD) and death.

Jiaye Liu, Tao Li, Li Zhang, Aiqiang Xu – 18 December 2018 – In actual clinical practice, infinite nucleos(t)ide analogues (NAs) treatment for chronic hepatitis B virus (HBV) infection is unrealistic. The most commonly used endpoint is suppression of HBV DNA to undetectable levels with normalization of alanine aminotransferase. However, this criterion for cessation of treatment is associated with various incidences of virological and clinical relapse.

Steven F. Solga, Marina Serper, Rebecca A. Young, Kimberly A. Forde – 18 December 2018 – Early liver transplantation for alcoholic hepatitis is a potentially life‐saving treatment. As this practice becomes increasingly common, however, the liver transplant community is taking a fresh look at a familiar challenge: best stewardship of donor organs. Herein, we examine a few basic, necessary ethical and practical concerns relevant to this indication.

Brian P. Lee, Eric Vittinghoff, Christine Hsu, Hyosun Han, George Therapondos, Oren K. Fix, David W. Victor, Deepti Dronamraju, Gene Y. Im, Michael D. Voigt, John P. Rice, Michael R. Lucey, Sheila Eswaran, Po‐Hung Chen, Zhiping Li, Haripriya Maddur, Norah A. Terrault – 18 December 2018 – Early liver transplant (LT) for alcohol‐associated disease (i.e., without a specific sobriety period) is controversial but increasingly used.

Loren Laine – 18 December 2018

Jie Wu, Yuqing Zhou, Xiaofang Fu, Min Deng, Yang Zheng, Guo Tian, Yiping Li, Chencheng Wang, Cheng Ding, Bing Ruan, Shigui Yang, Lanjuan Li – 18 December 2018 – The launch of new direct‐acting antivirals (DAAs) is expected to substantially reduce the burden of hepatitis C virus (HCV) in China. However, the effect of these changes has not yet been modeled in China. Therefore, we aim to predict the burden of HCV‐related diseases in China by simulating different scenarios that incorporate recent therapeutic advances of HCV and China’s current screening strategy.

Beatriz Aguilar‐Bravo, Daniel Rodrigo‐Torres, Silvia Ariño, Mar Coll, Elisa Pose, Delia Blaya, Isabel Graupera, Luis Perea, Júlia Vallverdú, Teresa Rubio‐Tomás, Laurent Dubuquoy, Carolina Armengol, Antonio Lo Nigro, Peter Stärkel, Philippe Mathurin, Ramon Bataller, Joan Caballería, Juan José Lozano, Pere Ginès, Pau Sancho‐Bru – 18 December 2018 – Chronic liver diseases are characterized by the expansion of ductular reaction (DR) cells and the expression of liver progenitor cell (LPC) markers.

Mar Riveiro‐Barciela, Merche Gironella, Alicia Senín, María‐Teresa Salcedo, Xavier Merino‐Casabiel, Lluis Castells, Rafael Esteban, Maria Buti, Fernando Martínez‐Valle – 18 December 2018

Jiaye Liu, Tao Li, Li Zhang, Aiqiang Xu – 18 December 2018 – In actual clinical practice, infinite nucleos(t)ide analogues (NAs) treatment for chronic hepatitis B virus (HBV) infection is unrealistic. The most commonly used endpoint is suppression of HBV DNA to undetectable levels with normalization of alanine aminotransferase. However, this criterion for cessation of treatment is associated with various incidences of virological and clinical relapse.

Samer Chehade, Paul C. Adams – 18 December 2018